Loading...
2CUREX logo

2cureX AB (publ)OM:2CUREX Stock Report

Market Cap SEK 44.2m
Share Price
SEK 1.76
My Fair Value
n/a
1Y-64.4%
7D-3.3%
1D
Portfolio Value
View

2cureX AB (publ)

OM:2CUREX Stock Report

Market Cap: SEK 44.2m

2cureX (2CUREX) Stock Overview

Operates as a medical technology company in Europe. More details

2CUREX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends2/6

2CUREX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

2cureX AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for 2cureX
Historical stock prices
Current Share PriceSEK 1.76
52 Week HighSEK 5.48
52 Week LowSEK 0.51
Beta0
1 Month Change-13.09%
3 Month Change28.47%
1 Year Change-64.37%
3 Year Change-66.15%
5 Year Change-89.33%
Change since IPO-78.14%

Recent News & Updates

Recent updates

Analysis Article Jun 03

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article Jan 06

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Sep 23

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Jun 02

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Feb 18

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
Analysis Article Nov 29

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

Ole Thastrup is the CEO of 2cureX AB (publ) (STO:2CUREX), and in this article, we analyze the executive's compensation...

Shareholder Returns

2CUREXSE Medical EquipmentSE Market
7D-3.3%-0.05%-1.9%
1Y-64.4%-11.5%9.6%

Return vs Industry: 2CUREX underperformed the Swedish Medical Equipment industry which returned -11.2% over the past year.

Return vs Market: 2CUREX underperformed the Swedish Market which returned 9.3% over the past year.

Price Volatility

Is 2CUREX's price volatile compared to industry and market?
2CUREX volatility
2CUREX Average Weekly Movement21.8%
Medical Equipment Industry Average Movement7.2%
Market Average Movement6.1%
10% most volatile stocks in SE Market14.4%
10% least volatile stocks in SE Market3.5%

Stable Share Price: 2CUREX's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: 2CUREX's weekly volatility has decreased from 29% to 22% over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
2006n/aNathaniel Hutleywww.2curex.se

2cureX AB (publ) operates as a medical technology company in Europe. Its proprietary IndiTreat test family creates various 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are effective for that specific tumor. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.

2cureX AB (publ) Fundamentals Summary

How do 2cureX's earnings and revenue compare to its market cap?
2CUREX fundamental statistics
Market capSEK 44.18m
Earnings (TTM)-SEK 26.35m
Revenue (TTM)SEK 1.98m
0.0x
P/S Ratio
0.0x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2CUREX income statement (TTM)
RevenueSEK 1.98m
Cost of RevenueSEK 9.61m
Gross Profit-SEK 7.63m
Other ExpensesSEK 18.72m
Earnings-SEK 26.35m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Aug 27, 2026

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did 2CUREX perform over the long term?

See historical performance and comparison

Dividends

4.8%
Current Dividend Yield
n/a
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 09:39
End of Day Share Price 2026/06/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

2cureX AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar BergmanRedeye